| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H28ClNO |
| Molecular Weight | 309.874 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCOC1(CCCCC1)C2=CC=C(Cl)C=C2
InChI
InChIKey=FFCARBNHUSWRGK-UHFFFAOYSA-N
InChI=1S/C18H28ClNO/c1-3-20(4-2)14-15-21-18(12-6-5-7-13-18)16-8-10-17(19)11-9-16/h8-11H,3-7,12-15H2,1-2H3
| Molecular Formula | C18H28ClNO |
| Molecular Weight | 309.874 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Clofenciclan is a dopamine-releasing agent, developed by Boehringer & Soehne in the 1950s for the treatment of Parkinson's disease. Compared to other anti-parkinsonian drugs of the time, clofenciclan lacked peripheral anticholinergic properties and caused pronounced stimulation of the central nervous system.
Approval Year
Patents
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 1 of 1 entries
